|
|
17 April 2020 |
Advanced Medical Solutions Group plc
(“AMS”, the “Company” or the “Group”)
Director/PDMR Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that on 14 April 2020, the Board, following a recommendation from the Remuneration Committee, granted new share options to the following Directors/PDMRs under the existing Advanced Medical Solutions Long Term Incentive Plan (the ‘LTIP’). The vesting of these options is based on achieving certain performance criteria for the three years prior to vesting. The performance criteria under the LTIP scheme is split equally between Earnings Per Share (EPS) growth against fixed targets and Total Shareholder Return (TSR) against a comparator group. The performance criteria have remained unchanged for the last six years.
|
Director/PDMR |
Options prior to grant |
Options granted |
Resultant LTIP holdings |
|
Chris Meredith Chief Executive Officer |
629,517
|
254,812
|
884,329
|
|
Eddie Johnson Chief Financial Officer |
138,126
|
72,197
|
210,323
|
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Chris Meredith |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Grant of 254,812 options under the Advanced Medical Solutions Long Term Incentive Plan on 14 April 2020 |
||||
|
c) |
Price(s) and volume(s):
|
||||
|
d) |
Aggregated information: Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 14/04/2020 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Eddie Johnson |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Grant of 72,197 options under the Advanced Medical Solutions Long Term Incentive Plan on 14 April 2020 |
||||
|
c) |
Price(s) and volume(s):
|
||||
|
d) |
Aggregated information: Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 14/04/2020 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
-End –
For further information, please contact:
|
Advanced Medical Solutions Group plc |
Tel: 44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer |
|
|
|
|
|
Consilium Strategic Communications |
Tel: 44 (0) 20 3709 5700 |
|
Mary-Jane Elliott / Matthew Neal / Olivia Manser |
AMS@consilium-comms.com |
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: 44 (0) 20 7597 5970 |
|
Daniel Adams / Gary Clarence / Patrick Robb |
|
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and wound care markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand®, RESORBA®, and LiquiBand® Fix8TM. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France.
AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees. For more information, please see www.admedsol.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHBUGDSRDBDGGR